Endocrine Abstracts

Background: While a considerable body of literature exists detailing outcomes in patients with adrenocortical carcinoma (ACC), reports specifically addressing a cohort of patients with recurrent disease remain scarce. Therefore, the objective of this study was to evaluate treatment outcomes in patients with recurrent ACC.Methods: In our cohort of 55 patients who underwent R0/Rx tumor resection between 2011 and 2022, 18 individuals (33%) exhibited recurre...

Introduction: Mitotane is an adrenolytic drug which is used in patients with adrenocortical carcinoma (ACC) and leads to adrenal insufficiency (AI). The aim of this study was to evaluate the time to recovery of the hypothalamus-pituitary-adrenal (HPA) axis after adjuvant mitotane treatment and to determine possible predictive factors.Materials and Methods: In this retrospective study, we included 19 patients with ACC, ENSAT stage I- III, who were treated...

Background: Pituitary surgery is the primary therapy for Cushing’s disease (CD). Basal cortisol level (BCL) is measured postoperatively to evaluate the immediate efficacy of surgical treatment, but no definitive cut-off value has yet been determined as reliable. Our pituitary-dedicated centre uses an arbitrary BCL less than 50 nmol/l as expected early remission marker, identifying all patients with higher BCL as a risk group for early surgical failure.<p class="abstex...